Aziyo Biologics, Inc. $50 Million Initial Public Offering

Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public offering of common stock by Aziyo Biologics, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “AZYO.”          

Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. 

The Davis Polk corporate team included partner Alan F. Denenberg and associates Ali DeGolia and Lawrence Edward Traylor Jr. The tax team included partner Mario J. Verdolini and associate Shay Moyal. Partner David R. Bauer and associates Jesse L. Hallock and Brette L. Trost provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.